Shots:

• The NMPA has approved Enlituo + CT (FOLFIRI), a biosimilar version of cetuximab beta, as a 1L treatment for RAS/BRAF wild-type metastatic colorectal cancer (mCRC)
• The approval was based on a P-II/III trial (n=505) evaluating cetuximab beta + CT vs CT, showing a PFS of 13.133mos. vs 9.567mos., an ORR of 69.1% vs 42.3% & OS of 2.322yrs. vs 1.900yrs. & a P-III confirmatory trial
• Enlituo (CMAB009), a recombinant EGFR mAb developed in partnership with Mabpharm, is categorized as a 2.4 class modified biologic & is produced by utilizing a protein production technology that prevents glycosylation modification which results in hypersensitivity

Ref: Simcere Zaiming | Image: Simcere Zaiming

Related Post:- Simcere Zaiming Entered into a Clinical Collaboration Agreement with MSD to Evaluate SIM0235 + Keytruda for Advanced Solid Tumors and Cutaneous T-cell Lymphoma

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com